



WellCare Health Plans, Inc.
The WellCare Group of Companies

Important Change to the Medicaid Preferred Drug List

July 7, 2009

Dear Provider:

WellCare of Georgia Medicaid is committed to providing physicians with important information about our Preferred Drug List (PDL).

In an effort to provide appropriate, safe and cost-effective drug therapy, WellCare will be making a change to the preferred long-acting basal insulin product.

Effective **July 1, 2009**, the WellCare Pharmacy & Therapeutics Committee has selected Levemir® as the preferred long-acting basal insulin on the PDL. Lantus® will be moved to non-preferred status. Members that are currently using Lantus® will be grandfathered and continued on this medication through December 31, 2009. All members that require a new prescription for long-acting basal insulin should be tried on Levemir® first.

We recognize that a number of patient-specific variables, which are not available to us, must be taken into account. You are best qualified to balance quality and care considerations in choosing the most appropriate medications for your patients. If you feel that your patient would benefit more from the use of the non-preferred product, you may request authorization using the Drug Evaluation Review form that can be located on our website, georgia.wellcare.com.

We appreciate your cooperation in considering Levemir® as our preferred product choice.

Sincerely,

WellCare of Georgia Pharmacy Department

WELLCARE OF GEORGIA, INC.
211 Perimeter Center Parkway
Suite 800
Atlanta, Georgia 30346
Telephone: (678) 327-0939
866-300-1141
Fax (678) 327-0944